SCHEMBL1475256

SCHEMBL1475256

CC(=O)N1CCN(C(=O)OCc2cc(-c3ccco3)on2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.59
NPC1 O15118 4/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
HPGD P15428 2/20 0.52
MAPT P10636 7/20 0.50
POLB P06746 6/20 0.50
ALDH1A1 P00352 5/20 0.47
CYP1A2 P05177 2/20 0.47
KMT2A Q03164 3/20 0.47
CACNA1B Q00975 1/20 0.47
APBA1 Q02410 1/20 0.47
LMNA P02545 4/20 0.47
MEN1 O00255 2/20 0.47
GAA P10253 2/20 0.46
THRB P10828 2/20 0.46
TSHR P16473 3/20 0.45
ALOX15 P16050 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
HSD17B10 Q99714 2/20 0.45
CYP2D6 P10635 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1474743 0.91 HPGD (0.64) RAB9ANPC1L3MBTL1HPGDMAPT
SCHEMBL14470267 0.86 RAB9A (0.56) RAB9ANPC1L3MBTL1HPGDMAPT
SCHEMBL1476803 0.79 RAB9A (0.58) RAB9ANPC1L3MBTL1HPGDMAPT
SCHEMBL14948947 0.73 RAB9A (0.55) RAB9ANPC1L3MBTL1HPGDMAPT
SCHEMBL1474285 0.72 RAB9A (0.64) RAB9ANPC1HPGDMAPTALDH1A1
SCHEMBL1476488 0.71 NPC1 (0.54) RAB9ANPC1L3MBTL1HPGDMAPT
SCHEMBL15190130 0.71 HPGD (0.47) RAB9ANPC1L3MBTL1HPGDMAPT
SCHEMBL1474697 0.70 RAB9A (0.56) RAB9ANPC1L3MBTL1HPGDMAPT
SCHEMBL14946441 0.70 RAB9A (0.52) RAB9ANPC1L3MBTL1HPGDMAPT
SCHEMBL1476492 0.69 NPC1 (0.56) RAB9ANPC1L3MBTL1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 RAB9A 2013/4885NPC1 2242/4885L3MBTL1 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.